Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory disease in infants and children. MEDI-493 (palivizumab, Synagis) is a humanized monoclonal IgG1 antibody to the fusion protein of RSV, and it is highly active in vitro against RSV A and B strains. To describe the safety, tol...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Pediatric infectious disease journal 1998-09, Vol.17 (9), p.787-791
Hauptverfasser:	Sáez-Llorens, X, Castaño, E, Null, D, Steichen, J, Sánchez, P J, Ramilo, O, Top, Jr, F H, Connor, E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal, Humanized Bronchopulmonary Dysplasia - immunology Humans Infant Infant, Newborn Infant, Premature Injections, Intramuscular Palivizumab Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Viruses - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!